Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

B-Lymphocytes Lymphoma, B-Cell T-Lymphocytes Antigens, CD19 Receptors, Antigen, T-Cell Hematopoietic Stem Cell Transplantation Humans Neoplasm Recurrence, Local Immunotherapy, Adoptive Research Articles 3. Good health
DOI: 10.1158/2326-6066.cir-22-0910 Publication Date: 2023-05-31T20:38:10Z
ABSTRACT
Abstract Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells, some patients relapse due to tumor escape and low or uneven expression, among other mechanisms. Therapeutic options after are limited, emphasizing need optimize current approaches. In addition, there is a develop allogeneic “off-the-shelf” therapies from healthy donors that readily available at time treatment decision can overcome limitations To address both challenges simultaneously, we generated CD20xCD22 dual CAR cell. Herein, demonstrate CD20x22 cells display robust, sustained dose-dependent activity in vitro vivo, while efficiently targeting primary B-cell non–Hodgkin lymphoma (B-NHL) samples with heterogeneous levels CD22 CD20. Altogether, provide preclinical proof-of-concept data for an cell mechanisms resistance T-cell B-NHL, providing potential alternative CD19 targeting.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (61)
CITATIONS (6)